Search Medical Condition
Please enter condition
Please choose location

Alsip, Illinois Clinical Trials

A listing of Alsip, Illinois clinical trials actively recruiting patient volunteers.

RESULTS

Found (217) clinical trials

Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis

This is a Phase 3, prospective, multicenter, multinational, open-label, randomized, two-arm, comparative study. Subjects who sign informed consent would undergo study-specific screening assessments within 35 days from the day of informed consent. On the day of surgery (Day 0), subjects could still be undergoing screening assessments, such as confirmation of ...

Phase

0.27 miles

Learn More »

A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer

The primary purpose of this research is to describe patient characteristics predictive of an imaging study positive for distant metastases in patients with castration-resistant prostate cancer and no known distant metastases.

Phase N/A

2.83 miles

Learn More »

The Equinox Study is a clinical research study that is evaluating an oral investigational medication to see if it may reduce moderate to severe pain associated with endometriosis. 

Phase

2.83 miles

Learn More »

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

The study is performed to assess the efficacy and safety of Vilaprisan in subjects with uterine fibroids compared to standard of care

Phase

2.83 miles

Learn More »

The Coflex COMMUNITY Study: An Observational Study of Coflex Interlaminar Technology

The purpose of the coflexCOMMUNITY observational study is to collect information on patients with spinal stenosis undergoing back surgery with the coflex implant, and to look at their outcomes and the cost-effectiveness of this procedure.

Phase N/A

2.83 miles

Learn More »

Safety and Efficacy Study of SUN-131 Transdermal System (TDS) as Compared to Placebo TDS in Patients With a Chalazion

This protocol for SUN-131 1.5% TDS is developed for the treatment of chalazion. SUN-131 1.5% TDS is designed for local delivery of a corticosteroid, to the upper or lower eyelid. The purpose of this study is to evaluate the efficacy and safety of SUN-131 1.5% TDS as compared with placebo ...

Phase

3.02 miles

Learn More »

Trial of Overminus Spectacle Therapy for Intermittent Exotropia

The main objectives of this randomized trial comparing overminus lens treatment to non-overminus (spectacles without overminus or spectacles with plano lenses) are to determine The long-term on-treatment effect of overminus treatment on distance IXT control score. The off-treatment effect of overminus treatment on distance IXT control score (following weaning and ...

Phase N/A

3.02 miles

Learn More »

Structured Discontinuation vs Continued Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioids for Chronic Pain

The purpose of this study is to evaluate the effect on pain intensity (PI) of structured discontinuation of long-term opioid analgesic therapy compared to continuation of opioid therapy in Suboptimal and Optimal Responders to high-dose, long-term opioid analgesic therapy for chronic low back pain (CLBP).

Phase

3.13 miles

Learn More »

Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission

The purpose of this study is to evaluate the efficacy of etanercept monotherapy compared to methotrexate monotherapy on maintenance of remission in subjects with Rheumatoid Arthritis who were on etanercept plus methotrexate therapy. This is a multicenter, randomized withdrawal, double-blind controlled study in subjects with Rheumatoid Arthritis on etanercept plus ...

Phase

3.14 miles

Learn More »

Efficacy Safety and Tolerability of Multiple Dosing Regimens of Oral AGN-241689 in Episodic Migraine Prevention

This study will evaluate the safety and tolerability of the following doses of AGN-241689: 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship.

Phase

3.14 miles

Learn More »